| The Institute of Human Virology, Nigeria is seeking bidders to bid for the Production of Information, Education and Communication (IEC) Materials under GF N-THRIP grant. | |
| Opening Date/ Time: | 9 July 2026 |
| Closing Date/ Time: | 30 July 2026 @10:00am |
| For more on this bid, kindly download the complete bid document, | Click here to download the bidding document |
Bid Advert | AI Driven SC for TB HIV Commodities | 9 July 2026
| The Institute of Human Virology, Nigeria is seeking bidders to bid for the Development and National Deployment of an Integrated HTM Quantification, Pipeline Monitoring and Inventory Intelligence Platform for Nigeria (QuantifyNG): AI-Driven Supply Chain Intelligence for Uninterrupted TB/HIV Commodities in Nigeria under GF N-THRIP grant. | |
| Opening Date/ Time: | 9 July 2026 |
| Closing Date/ Time: | 30 July 2026 @10:00am |
| For more on this bid, kindly download the complete bid document, | Click here to download the bidding document |
IRCE Announces Launch of Lassa Fever Survivors Research
The Institute of Human Virology Nigeria (IHVN), through its International Research Center of Excellence (IRCE), has announced the launch of a research study to understand how Lassa fever survivors fight and overcome Lassa virus (LASV) infection.
The study, titled “Identification and Immunologic Characterization of Adult Lassa Fever Survivors in Nigeria”, is a collaboration between IHVN-IRCE, the Abubakar Tafawa Balewa University Teaching Hospital (ATBUTH) in Bauchi State, and the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine.
Despite being endemic in West Africa for several decades with high case fatality rates, critical gaps remain in our understanding of how natural infection confers immunity in those that survive Lassa Fever, and how vaccine development can benefit from such knowledge. This 12-month collaborative study will seek to generate deeper insight into natural immunity following infection. The data generated will serve as a critical reference point for ongoing and future Lassa fever vaccine trials.
This study will also work with communities to minimize known risk factors and establish a repository of clinical data and biological samples — a valuable long-term scientific resource for the research community. This work will leverage ATBUTH’s and IHVN’s existing world-class laboratory infrastructure. The infrastructure includes its ISO 15189:2022 accredited laboratory in Jos, Plateau State (PLASVIREC), the Institute’s regional biorepository facility (I-HAB) located on the IHVN campus in Abuja and ATBUTH’s molecular diagnostic laboratory- Molecular Genetics and Infectious Disease Research Laboratory.
Speaking at the launch, Professor Alash’le Abimiku, the Nigerian Principal Investigator and Executive director of IHVN-IRCE stated: “This study represents an important step forward in our collective efforts to better work with communities to reduce behaviors and exposures that increase the risk of Lassa virus infection. By studying Lassa fever survivors in Nigeria, we are generating locally grounded evidence that will directly inform vaccine development and ultimately save lives.”
The research reflects IHVN’s enduring commitment to advancing health through science, strengthening in-country research capacity, and ensuring that African populations are active participants in and beneficiaries of the knowledge generated through research.
Prof. Yusuf Bara Jibril, the Chief Medical Officer of ATBUTH highlighted the importance of this study for communities like his in Bauchi that have experienced a surge of Lassa fever cases since November 2026: “Our communities need to be sensitized about Lassa fever and how to protect themselves from getting infected. A Lassa fever vaccine is even more relevant and important now and we as a teaching hospital for the state will continue to partner to make this a reality for our people”.
Dr. Suleiman Yusuf, the Lead Collaborator at ATBUTH commented: “Bauchi State has the clinical and laboratory infrastructure to contribute to knowledge that will lead to prevention and treatment of Lassa Fever. In addition, my institution has a long-term relationship with communities to ensure that knowledge on how to prevent Lassa fever transmission is sustained in each community and that health workers recognize clinical symptoms of Lassa for prompt intervention.”
“We are excited to collaborate with colleagues in Nigeria and contribute to global efforts to develop effective vaccines against Lassa fever” says Dr. Justin Ortiz, Professor at the University of Maryland School of Medicine Center for Vaccine Development and Global Health in Baltimore, USA, and a Co-investigator of the study.
“Studying the natural immune responses of Lassa fever survivors may help identify immune pathways and markers associated with recovery and protection following infection. These findings can provide important scientific context for ongoing efforts to design and evaluate future Lassa fever vaccines” says Matthias J. Schnell, PhD, Director of the Jefferson Center for Vaccines and Pandemic Preparedness at Thomas Jefferson University. Dr. Schnell is the Principal Investigator of the parent NIH contract and the Inventor of a Lassa fever vaccine candidate.
Lassa fever remains one of the most significant and persistent public health threats in Nigeria and the rest of West Africa where it is endemic. It is a zoonotic disease caused by the Lassa virus, an Old World arenavirus whose primary host is the rat referred to as Mastomys natalensis. Transmission to humans occurs primarily through contact with food or household items contaminated by rodent urine or feces.
The Nigeria Centre for Disease Control (NCDC) has already reported a case fatality rate of 25.1% in the year 2026 with outbreaks across 21 of Nigeria’s 37 states and 85% of cases concentrated in Bauchi, Ondo, Taraba, Benue, and Edo states. There is currently no licensed vaccine for Lassa fever although there are several efforts including that by CEPI to find an effective vaccine against Lassa.
Study and Data Coordinator – Digital Health for Key Populations in HIV Care and Prevention | Abuja
The Institute of Human Virology (IHVN) is a leading and reputable non-governmental organization addressing infectious and non-infectious diseases such as HIV, tuberculosis, and cancer through prevention, diagnosis, treatment, capacity building, research, care, and support services. IHVN is in partnership with local and international organizations and the different tiers of the government of Nigeria at the national, state, and local levels. The Institute aims to provide quality health services, capacity building, and research in West Africa and beyond.
To further drive quality and engender global best practices in HIV and TB care and treatment, this advert is therefore seeking qualified candidates for the following position:
| Position | Study and Data Coordinator – Digital Health for Key Populations in HIV Care and Prevention |
| Department | International Research Centre of Excellence |
| Location | Abuja |
Opening Date: 7th July, 2026
Closing Date: 20th July, 2026
Position Overview
IHVN is seeking a dedicated and passionate Study and Data Coordinator to join our team and play a crucial role in a groundbreaking project focused on improving HIV care and prevention among key populations through digital health interventions. The successful candidate will work closely with the healthcare providers and key population civil society organization to ensure the smooth execution of the project, as well as actively engage key population community members in the process.
Key Responsibilities
- Lead the day-to-day coordination and management of the digital health project for key populations.
- Collaborate with the research team to develop and refine project objectives, timelines, and deliverables.
- Ensure that project activities are executed in compliance with ethical guidelines and regulations.
- Establish and maintain strong relationships with key population groups.
- Conduct outreach and community mobilization efforts to ensure active participation in the project.
- Act as a liaison between the project team and key population communities to address concerns and facilitate communication.
- Oversee the deployment of digital health interventions, including mobile apps, and other technology-based solutions.
- Support Data Officers in training healthcare staff and key population participants on the use of digital tools, monitor participant use of the digital health app, and ensure their ongoing engagement.
- Work with the digital health app development team to develop and update app content, as well as troubleshooting issues.
- Monitor and evaluate the effectiveness of digital health interventions in improving HIV care and prevention.
- Collaborate with data analysts to collect, manage, and analyze project data.
- Ensure the accuracy and integrity of data collected from key population participants.
- Work with data officers and data management staff to ensure that data submission, quality control (QC), error correction, data processing and entry are functioning smoothly.
- Identifies and follows up on delinquent data and serves as back-up to the data manager.
- Responsible for system/account maintenance for site staff to access the REDCap web portal and other data management applications. The CRS Coordinator will work with the CRC.
- Conduct data quality assurance activities for the study sites.
- Prepare regular progress reports and contribute to research publications.
- Implement quality assurance measures to ensure that project activities meet established standards.
- Conduct regular assessments and make recommendations for improvements.
- Work closely with healthcare providers, researchers, and community organizations to align project activities with broader healthcare initiatives.
- Participate in team meetings and provide input on project strategies and goals.
Educational qualifications and experience
- Education:
- Bachelor’s degree in public health, social sciences, or a related field
- Registered with the health professional council or general nursing council of Nigeria
- Psychosocial counselling
- Human subject protection and good clinical practice training
- Experience:
- Previous experience in coordinating research or healthcare projects, particularly in the field of HIV prevention or key population engagement.
- Strong understanding of digital health technologies and their application in healthcare settings.
- Experience with Microsoft, Excel, Access, MS SQL Server, MySQL, electronic medical record systems, and REDCap
- Excellent communication and interpersonal skills, with the ability to engage with diverse communities.
- Knowledge of ethical considerations related to working with key populations and vulnerable communities.
- Demonstrated ability to work both independently and as part of a multidisciplinary team.
- Sensitivity to cultural and social issues impacting key populations in HIV care and prevention.
Safeguarding (PSEAH):
As an organization, IHVN takes the issue of Protection against Sexual Exploitation, Abuse and Harassment (PSEAH) seriously, because safeguarding the people we interface with in all our programmatic work is of the utmost importance to us.
IHVN only recruits’ representatives who are suited and abides to the strict responsibility of SEAH.
By applying to this role, you are agreeing to IHVN carrying out a background check on you with respect to SEAH records and you also confirm that not before or after being hired will you breach the IHVN policy on SEAH.
Equal employment opportunity statement
IHVN is an equal employment employer. We do not engage in practices that discriminate against any person employed or seeking employment based on religion, gender, national or ethnic origin, age, marital status, genetic information, or any other status or characteristic protected under applicable laws.
Mode of Application:
- Application letter, detailed curriculum and contact information for two professional references vitae in Microsoft Word format should be forwarded to the Assistant Director, Human Resources through this email address: [email protected] This e-mail address is being protected from spambots. You need JavaScript enabled to view it
- This advert is open from 20th July, 2026 and only shortlisted candidates will be contacted.
Bid Advert | Upgrade of IHVN N-THRIP DHIS2 Instance under GF N-THRIP grant | 26th June 2026
| The Institute of Human Virology, Nigeria is seeking bidders to bid for the Upgrade of IHVN N-THRIP DHIS2 Instance under GF N-THRIP grant | |
| Opening Date/ Time: | 26th June 2026 |
| Closing Date/ Time: | 17th July 2026 @10:00am |
| For more on this bid, kindly download the complete bid document, | Click here to download the bidding document |